Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Table 3 Logistic regression analyses using signature scores to predict CDAI nonremission at 6 months of biologic therapy

Drug	Gene set	Univariate analysis			Multivariate analysis^a
Drug	Gene set	OR	95 % CI	p Value	OR	95 % CI	p Value
IFX
	Inflammasomes	1.81	(1.23–2.78)	0.00382	1.72	(1.14–2.71)	0.00873
TCZ
	Specific CD19 (Watkins et al., 2009 [15])	0.24	(0.05–0.72)	0.02677	0.16	(0.02–0.71)	0.01327
ABT
	Elongation arrest and recovery	5.73	(1.47–49.11)	0.04488	6.85	(1.09–4426.71)	0.03309
	Specific CD56 (Watkins et al., 2009 [15])	3.25	(1.18–12.43)	0.04179	6.46	(1.60–88.39)	0.00388

Abbreviations: CDAI clinical disease activity index, IFX infliximab, TCZ tocilizumab, ABT abatacept, OR odds ratio, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, MTX methotrexate, ESR erythrocyte sedimentation rate
^aMultivariate analysis adjusted for significant (p < 0.1) variables as in Additional file 4 (IFX: female, concomitant csDMARD use [except MTX], ESR, CDAI; TCZ: disease duration, CDAI; ABT: disease duration, concomitant steroid use)

ISSN: 1478-6362